John K. Bakewell
John K. Bakewell's purchase track record
John K. Bakewell has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/10/2024 | TMCI | $595K | +32.2% | +83.6% | +14.8% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
STIM shifts focus from devices to psychedelic infrastructure. Neuronetics announced it is moving away from solely manufacturing its TMS device and is building a platform to support psychedelic therapies. The change aims to broaden the company's role in the emerging mental-health market. The stock is currently trading near its $1.19 support level and has an RSI of 25.4, indicating a low momentum environment.
Transaction History
| XTNT | ▲ Buy | Grant | 215,517 | $0 | 8/15/2026 | View on chart |
| TMCI | ▲ Buy | Grant | 30,000 | $0 | 5/19/2026 | View on chart |
| XTNT | ▲ Buy | Grant | 158,228 | $0 | 11/15/2025 | View on chart |
| TMCI | ▲ Buy | Grant | 23,917 | $0 | 5/20/2025 | View on chart |
| XTNT | ▲ Buy | Grant | 162,162 | $0 | 8/15/2024 | View on chart |
| TMCI | ▲ Buy | Grant | 15,091 | $0 | 5/21/2024 | View on chart |
| TMCI | ▲ Buy | Open Market | 130,000 | $595K | 5/10/2024 | View on chart |
| XTNT | ▲ Buy | Grant | 145,180 | $0 | 8/15/2023 | View on chart |
| STIM | ▲ Buy | Grant | 36,364 | — | 5/25/2023 | View on chart |
| STIM | ▼ Sell | Open Market | 14,400 | $39K | 5/24/2023 | View on chart |
| TMCI | ▲ Buy | Grant | 2,753 | $0 | 5/23/2023 | View on chart |
| XTNT | ▲ Buy | Grant | 215,415 | $0 | 8/15/2022 | View on chart |
| STIM | ▲ Buy | Grant | 38,910 | — | 5/26/2022 | View on chart |
| TMCI | ▲ Buy | Grant | 2,295 | $0 | 5/17/2022 | View on chart |
| XTNT | ▲ Buy | Grant | 85,337 | $0 | 8/15/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
Treace Medical Shares Five-Year Bunion Study Results
Treace Medical Concepts published five-year clinical results for its bunion treatment, aiming to strengthen evidence for broader adoption. This scientific update provides context for the stock's current position, which is trading near a key support level and below the average analyst price target.
Treace Medical Shares Five-Year Bunion Study Results. Treace Medical Concepts published five-year clinical results for its bunion treatment, aiming to strengthen evidence for broader adoption. This scientific update provides context for the stock's current position, which is trading near a key support level and below the average analyst price target.